开放标签的Ib/II期临床研究(COMPASSION-03/AK104-201)成果发表于10月2日的《柳叶刀·肿瘤学》(The Lancet Oncology, 影响因子51.1),题为:Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibo...
组合抗体(Bispecific Antibody),是指一个抗体分子可以与两个不同抗原或同一抗原的两个不同抗原表位相结合,这一特征赋予了该类分子很大的灵活性。针对免疫检查点(PD-1/PD-L1,CTLA-4等)的组合抗体数量也在快速增长。齐鲁制药旗下的...
2023年10月2日,北京大学肿瘤医院季加孚教授、沈琳教授和复旦大学附属肿瘤医院吴小华教授团队合作,在《柳叶刀·肿瘤学》(The Lancet Oncology)发表了题为:Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a mult...
开放标签的Ib/II期临床研究(COMPASSION-03/AK104-201)成果发表于10月2日的《柳叶刀·肿瘤学》(The Lancet Oncology, 影响因子51.1),题为:Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with...
(PD-1/CTLA-4双特异性抗体)治疗晚期实体瘤的多中心、开放标签的Ib/II期临床研究(COMPASSION-03/AK104-201)成果发表于10月2日的《柳叶刀·肿瘤学》(TheLancetOncology,影响因子51.1),题为:Safetyandantitumouractivityofcadonilimab,ananti-PD-1/CTLA-4bispecificantibody,forpatientswithadvancedsolidtumours(COMPASSION...
由北京大学肿瘤医院暨北京市肿瘤防治研究所、消化系肿瘤整合防治全国重点实验室、恶性肿瘤转化研究北京市重点实验室季加孚教授、沈琳教授和复旦大学附属肿瘤医院吴小华教授团队联合发表题为:Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tum...
卡度尼利单抗(PD-1/CTLA-4双抗) 作为全球首款上市的肿瘤免疫双抗,康方生物的卡度尼利单抗(PD-1/CTLA-4)在肺癌领域的探索,聚焦的是一线标准治疗失败的广大市场人群,也符合近年来FDA和CDE对双抗领域的要求,防止过度内卷,解决PD-1抗体尚未满足的临床需求。 在肺癌领域,PD-1/L1抑制剂联合化疗已成为晚期非小...
参考文献 Xinghua Pang, Zhaoliang Huang, Tingting Zhong et al. Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity.mAbs 2023
(COMPASSION-03/AK104-201)成果发表于10月2日的《柳叶刀·肿瘤学》(The Lancet Oncology, 影响因子51.1),题为:Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2...
(PD-1/CTLA-4双特异性抗体)治疗晚期实体瘤的多中心、开放标签的Ib/II期临床研究(COMPASSION-03/AK104-201)成果发表于10月2日的《柳叶刀·肿瘤学》(TheLancetOncology,影响因子51.1),题为:Safetyandantitumouractivityofcadonilimab,ananti-PD-1/CTLA-4bispecificantibody,forpatientswithadvancedsolidtumours(COMPASSION...